Evidence map›Paper›PMID 34956224›Full record

ArticleFrontiers in immunology2021

YAP/TAZ: Key Players for Rheumatoid Arthritis Severity by Driving Fibroblast Like Synoviocytes Phenotype and Fibro-Inflammatory Response.

Robin Caire, Estelle Audoux, Guillaume Courbon, Eva Michaud, Claudie Petit, Elisa Dalix, Marwa Chafchafi, Mireille Thomas, Arnaud Vanden-Bossche, Laurent Navarro and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Bone organoids and mitochondrial reprogramming.Journal of orthopaedic translation · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Bone organoid construction and evolution.Journal of orthopaedic translation · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Research progress on Hippo signaling pathway effector molecules in rheumatic immune system diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Robin CaireINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Estelle AudouxCIRI (Centre International de Recherche en Infectiologie), Equipe GIMAP (Team 15), INSERM, U1111, CNRS, ENS, UCBL1, Université Jean Monnet, Université de Lyon, Saint-Etienne, France.
Guillaume CourbonINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Eva MichaudCIRI (Centre International de Recherche en Infectiologie), Equipe GIMAP (Team 15), INSERM, U1111, CNRS, ENS, UCBL1, Université Jean Monnet, Université de Lyon, Saint-Etienne, France.
Claudie PetitINSERM, U1059-SAINBIOSE, Mines Saint-Etienne, Université de Lyon, Saint-Etienne, France.
Elisa DalixINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Marwa ChafchafiINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Mireille ThomasINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Arnaud Vanden-BosscheINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Laurent NavarroINSERM, U1059-SAINBIOSE, Mines Saint-Etienne, Université de Lyon, Saint-Etienne, France.
Marie-Thérèse LinossierINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Sylvie PeyrocheINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Alain GuignandonINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Laurence VicoINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Stephane PaulCIRI (Centre International de Recherche en Infectiologie), Equipe GIMAP (Team 15), INSERM, U1111, CNRS, ENS, UCBL1, Université Jean Monnet, Université de Lyon, Saint-Etienne, France.
Hubert MarotteINSERM, U1059-SAINBIOSE, Université de Lyon, Saint-Etienne, France.
Université Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The role of YAP/TAZ, two transcriptional co-activators involved in several cancers, was investigated in rheumatoid arthritis (RA). Methods: Fibroblast like synoviocytes (FLS) from patients with RA or osteoarthritis were cultured in 2D or into 3D synovial organoids. Arthritis rat model (n=28) and colitis mouse model (n=21) were used. YAP/TAZ transcriptional activity was inhibited by verteporfin (VP). Multiple techniques were used to assess gene and/or protein expression and/or localization, cell phenotype (invasion, proliferation, apoptosis), bone erosion, and synovial stiffness. Results: YAP/TAZ were transcriptionally active in arthritis (19-fold increase for CTGF expression, a YAP target gene, in RA Conclusion: Our work reveals that YAP/TAZ were critical factors during arthritis. Thus, their transcriptional inhibition could be relevant to treat inflammatory related diseases.

Indexed as

AnimalsArthritis, RheumatoidCells, CulturedColitisHumansInflammationMiceOsteoarthritisPhenotypeRatsSynoviocytesTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling ProteinsTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling Proteinsinflammationinflammatory bowel diseasemechanotransductionrheumatoid arthritisYAP

Identifiers

PMID34956224
PMCPMC8695934
OpenAlexW4200004252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.